MAbs against membrane proteins are notoriously difficult to isolate

Integral Molecular is uniquely capable of isolating MAbs against multipass membrane proteins

Traditional discovery platforms produce small panels of non-functional MAbs

Our MPS Antibody Discovery platform delivers large panels of functional MAbs
MPS Antibody Discovery

“Access to Integral Molecular’s capabilities complements our ability to advance our therapeutic pipeline, which is dedicated to delivering novel antibody therapeutics to patients.”
- CECILE GEUIJEN, PhD, VP OF ONCOLOGY RESEARCH, MERUS
Delivering Antibodies for Difficult Targets
Optimized Antigen Expression
We engineer target proteins for increased expression, stability, and enhanced surface trafficking, using proprietary techniques
Native Epitope Targeting
Protein (Lipoparticle) and DNA immunization with proprietary adjuvants are used to ensure maximal immune responses against a protein’s native conformation
Access to Diverse Epitopes
We target even conserved epitopes by using chickens for immunization, enabling maximal epitope coverage and MAb developability and dual specificity for human and rodent orthologs
Large Panels of Diverse Antibodies
- ✓ Picomolar affinity
- ✓ Isoform-selective
- ✓ Agonists
- ✓ Antagonists
- ✓ State-specific
High-Throughput, Deep Screening Technologies
We use Lipoparticle-phage display strategies with protocols specifically tailored to the challenges of membrane proteins to isolate rare and diverse MAbs against native epitopes
Our proprietary microfluidic B cell cloning platform allows high-throughput screening of millions of B cells isolated directly from immunized animals
Antibody Selection and Optimization
Lead Selection
Leads are selected based on functional testing, binding affinity, epitope location (Shotgun Mutagenesis), and specificity profiling (Membrane Proteome Array)
Lead Optimization
Leads are optimized for developability and preclinical testing, including:
- Fc reformatting
- Minimized immunogenicity
- Affinity maturation
“We have been impressed by Integral Molecular’s membrane protein expertise and their proven record in discovering antibodies against them.”
- HIDEAKI TADA, EXECUTIVE DIRECTOR, CENTER OF ONCOLOGY RESEARCH, ONO PHARMACEUTICAL CO., LTD.
Featured Case Studies

Frequently Asked Questions
The final deliverable of an MPS Antibody Discovery project is usually a panel of highly specific, diverse, and functional MAbs that meet the customer’s specifications. Using our MPS Antibody Discovery platform, we have a very high success rate (>95%) in delivering such MAb panels. In addition to the final deliverable, customers receive 4 progress reports during their MPS project:
- 1. Target Expression Report – Summarizes target expression after engineering and the proposed immunization strategy
- 2. Serum Reactivity Report – Summarizes the immune response of each animal to the target protein
- 3. Clone Screen Report – Summarizes MAb selection results and the diversity of discovered MAbs
- 4. Clone Reactivity Report – Summarizes target reactivity and the full sequence of each validated MAb. This report is provided simultaneously with 100 μg of purified, ready-to-use IgG of each validated MAb for customer testing
